Shining the omics microscope on the mechanism of action of compounds used in HIV cure strategies
Vorinostat is currently being evaluated in clinical trials in a shock and kill approach to cure HIV. Transcriptomic and proteomic profiling of Vorinostat in primary CD4 T cells has identified noteworthy off-target effects, subject-to-subject variation, as well as biomarkers that may be monitored to confirm compound exposure.
Date:
30 April 2015, 12:00 (Thursday, 1st week, Trinity 2015)
Venue:
Medawar Building, off South Parks Road OX1 3SY
Venue Details:
Seminar Room 30, Call 281880 on arrival for entry
Speaker:
Dr Christopher Woelk (Department of Medicine at the University of Southampton)
Organising department:
Nuffield Department of Clinical Medicine
Organiser:
Chris Willberg (NDM Experimental Medicine)
Part of:
Peter Medawar Building Seminars
Booking required?:
Not required
Audience:
Members of the University only
Editors:
Anne Bowtell,
Chris Willberg
